Dykema Advises PowerUp Acquisition Corp. in Aspire Biopharma’s Nasdaq Listing

Congratulations to Dykema’s client, PowerUp Acquisition Corp., in its successful business combination with Aspire Biopharma Holdings, Inc. (Nasdaq: ASBP), a developer of patent-protected disruptive drug delivery mechanism technology. Following the closing of the transaction on February 17, 2025, Aspire Biopharma’s common stock and warrants will begin trading on the Nasdaq Global Market and Nasdaq Capital Market under the ticker symbols “ASBP” and “ASBPW,” respectively, starting February 20, 2025.

The business combination, approved by PowerUp Acquisition Corp. stockholders on January 31, 2025, will provide Aspire Biopharma with enhanced access to capital, support its strategic growth initiatives, and accelerate the development of its novel fast-absorbing aspirin for cardiac emergencies, a candidate for fast-track FDA approval.

Dykema’s legal team advised PowerUp Acquisition Corp. on the structuring, negotiation, and execution of the transaction. The firm’s representation included providing strategic guidance on regulatory matters, corporate governance, securities compliance, and the complexities of the SPAC merger process.

The Dykema team assisting with this transaction was led by Kate Bechen and included Hallie Heath, Andrew Frost, Robin Lehninger, and Jill Knutson.